This is a limited company view. Sign up for a Free Trial to see everything.

Developing breakthrough platforms for long acting non-viral gene therapy for ocular diseases

Biotechnology
Healthcare
Pharmaceuticals

Overview

Location

Paris

Founded

Employees

0

Stage

Exited

Total funding

$10M

Last funding

a year ago

Acquisitions

0

Growth score

36

Mindshare score

36

Scoring

Deals

$10.0M Series A

Pontifax

Sep 15, 2016

Undisclosed Amount Undisclosed Round

Boehringer Ingelheim Venture Fund

Apr 11, 2013

Employee Growth

Use Eyevensys's historical employee count to better understand their growth and spending over time.

Unlock with a Free Trial

Mobile

Use Eyevensys's mobile downloads and app ranks to evaluate the performance of their mobile apps.

Unlock with a Free Trial

Similar Companies

Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals, Inc. (Nasdaq: MGDL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.
No Known Funding

Gain context with Mattermark Salesforce Enrichment

Find out how

Notes